Immunome Inc's (NASDAQ:IMNM) shares climb on word its three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against SARS-CoV-2 Lambda (C.37) and Delta AY.1/2 (Delta Plus) variants in preclinical testing.
IMM-BCP-01 consists of three antibodies that bind to non-overlapping regions of the spike protein and show combinatorial activity against multiple strains of SARS-CoV-2.
The project was funded by the U.S. Department of Defense in collaboration with the Defense Health Agency
Said CEO Purnanand Sarma, "IMM-BCP-01 continues to demonstrate its broad neutralizing activity against emerging SARS-CoV-2 variants in preclinical testing, most recently against the Lambda and Delta plus variants.
"While the Delta lineage is the dominant strain in the U.S., the Lambda variant is rapidly spreading through South America, and is a designated variant of interest by World Health Organization (WHO). IMM-BCP-01 was designed to be resistant to SARS-CoV-2 variants, and we are delighted that our approach continues to be supported by our preclinical data."
Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated.
The company’s initial focus is developing therapeutics to treat oncology and infectious diseases, including COVID-19. Immunome’s proprietary discovery engine identifies novel therapeutic antibodies and their targets by leveraging the highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease
IMNM shares are up $1.73, or 11.5%, at $16.83 early Tuesday.
